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A limited number of Pseudomonas aeruginosa genotypes (mainly ST-111, ST-175, and ST-235), known as high-risk clones,
are responsible for epidemics of nosocomial infections by multidrug-resistant (MDR) or extensively drug-resistant (XDR)
strains worldwide. We explored the potential biological parameters that may explain the success of these clones. A total of
20 isolates from each of 4 resistance groups (XDR, MDR, ModR [resistant to 1 or 2 classes], and MultiS [susceptible to all
antipseudomonals]), recovered from a multicenter study of P. aeruginosa bloodstream infections performed in 10 Spanish
hospitals, were analyzed. A further set of 20 XDR isolates belonging to epidemic high-risk clones (ST-175 [n  6], ST-111
[n  7], and ST-235 [n  7]) recovered from different geographical locations was also studied. When unknown, genotypes
were documented through multilocus sequence typing. The biological parameters evaluated included twitching, swim-
ming, and swarming motility, biofilm formation, production of pyoverdine and pyocyanin, spontaneous mutant frequen-
cies, and the in vitro competition index (CI) obtained with a flow cytometry assay. All 20 (100%) XDR, 8 (40%) MDR, and 1
(5%) ModR bloodstream isolate from the multicenter study belonged to high-risk clones. No significant differences were
observed between clonally diverse ModR and MultiS isolates for any of the parameters. In contrast, MDR/XDR high-risk
clones showed significantly increased biofilm formation and mutant frequencies but significantly reduced motility (twitch-
ing, swimming, and swarming), production of pyoverdine and pyocyanin, and fitness. The defined biological markers of
high-risk clones, which resemble those resulting from adaptation to chronic infections, could be useful for the design of
specific treatment and infection control strategies.
The increasing prevalence of nosocomial infections producedby multidrug-resistant (MDR) or extensively drug-resistant
(XDR) Pseudomonas aeruginosa strains severely compromises the
selection of appropriate treatments and is therefore associated
with significant morbidity and mortality (1–3). This growing
threat results from the interplay of the extraordinary capacity of
this pathogen for developing resistance to nearly all available an-
tibiotics by the selection of mutations in chromosomal genes and
from the increasing prevalence of transferable resistance determi-
nants, particularly those encoding class B carbapenemases (metal-
lo--lactamases [MBLs]) or extended-spectrum -lactamases
(ESBLs), frequently cotransferred with genes encoding aminogly-
coside-modifying enzymes (4). Over the last decade, multiple re-
ports have warned about the epidemic dissemination of XDR/
MDR strains in multiple hospitals (5–10). Even more concerning
are recent reports which have provided evidence of the exis-
tence of MDR/XDR clones of P. aeruginosa disseminated in
multiple institutions worldwide, denominated epidemic high-
risk clones (11). Among them, ST-111, ST-175, and ST-235 are
the most widespread (12–18). Moreover, in a recent multi-
center study of P. aeruginosa bloodstream infections, we
showed that all XDR isolates (10.5% of all isolates) and some
MDR isolates belonged to the epidemic high-risk clones, which
were not detected among susceptible isolates (19); the specific
genetic resistance markers of these clones, which may include
multiple combinations of chromosomal mutations and/or hor-
izontally acquired resistance elements, were also described in
detail for the first time (19).
The global success of bacterial pathogens is expected to be de-
termined by a complex interplay between pathogenicity, epide-
micity, and antibiotic resistance (20). The fitness cost of antibiotic
resistance mechanisms (21), the existence of regulatory networks
interconnecting resistance and virulence (22, 23), and natural ge-
netic engineering linking antibiotic resistance determinants
and clonal success through genetic capitalism (24) are thought
to be the main elements of this intricate equation (25). While
the impacts on virulence and fitness of several individual anti-
biotic resistance mechanisms of P. aeruginosa have been eval-
uated (26–28), the specific adaptive traits that may explain the
global success of epidemic high-risk clones remains unex-
plored. Since understanding the reasons for the success of these
clones could be crucial for designing specific treatment and
infection control strategies (29), the objective of this work was
to determine the potential underlying biological parameters.
For this purpose, using a large collection of well-characterized
strains with different resistance profiles from a Spanish multi-
center study of bloodstream infections (19, 30) and control
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XDR epidemic high-risk clones from different hospitals, we
analyzed a panel of 8 biological parameters that could poten-
tially be involved. These parameters included the three types of
bacterial motility (swimming, twitching, and swarming), the
capacity to form biofilms, the production of the siderophore
pyoverdine and the pyocyanin phenazine toxin, fitness (com-
petitive growth), and spontaneous mutation rates.
MATERIALS AND METHODS
Bacterial strains, definition of resistance profiles, and molecular typing.
A total of 100 well-characterized P. aeruginosa isolates were evaluated.
Recent consensus recommendations (31) were used to define MDR (non-
susceptible to 3 classes) and XDR (nonsusceptible to all but 1 or 2
classes) strains, considering the following 7 antimicrobial classes: cepha-
losporins (ceftazidime or cefepime), penicillin–-lactamase inhibitor
combinations (piperacillin-tazobactam), monobactams (aztreonam),
carbapenems (imipenem or meropenem), fluoroquinolones (ciprofloxa-
cin), aminoglycosides (gentamicin, tobramycin, or amikacin), and poly-
myxins (colistin). Strains susceptible to all tested antipseudomonal agents
were included in the multisusceptible (MultiS) category, and those non-
susceptible to at least one agent in 1 or 2 classes were included in the
moderately resistant (ModR) category. We studied the 20 XDR isolates
(10.5% of all 190 isolates analyzed) recovered from 7 of the 10 Spanish
hospitals participating in a 2008-2009 multicenter study of P. aeruginosa
bloodstream infections (19, 32). The same number (n  20) of isolates
from each of the other three susceptibility categories (MDR, ModR, and
MultiS) was randomly selected from the collection, with the only criteria
being maximum coverage of different hospitals. MICs were determined in
a previous study by broth microdilution following Clinical and Labora-
tory Standards Institute (CLSI) guidelines and breakpoints (19, 32). Like-
wise, the involved mutation-driven and horizontally acquired resistance
mechanisms of these strains were previously characterized in detail (19,
32). Additionally, the study included a panel of 20 XDR isolates belonging
to epidemic high-risk clones (ST-175 [n  6], ST-111 [n  7], and ST-235
[n  7]) recovered from different types of infections in different hospitals
and presenting multiple combinations of chromosomal resistance mech-
anisms and/or horizontally acquired -lactamases (VIM-1, VIM-2, VIM-
13, VIM-20, GES-5, or VEB-1) (8, 14, 17, 18, 33–35). In cases where they
were unknown, genotypes were documented through multilocus se-
quence typing (MLST) using previously described schemes, protocols,
available databases, and tools (36; http://pubmlst.org/paeruginosa). The
minimum spanning tree (MST) figure was constructed using Bionumer-
ics 7.0 software (Applied Maths, St.-Martens-Latem, Belgium).
Motility assays. (i) Swimming motility. Swimming medium (10 g/li-
ter tryptone, 5 g/liter NaCl, and 0.3% [wt/vol] midresolution agarose)
plates were inoculated with isolated colonies from an overnight culture in
LB agar (10 g/liter tryptone, 5 g/liter yeast extract, 10 g/liter NaCl, and 1%
agar) at 37°C by use of a sharp sterile toothpick, introducing it to up to half
the thickness of the medium (37).
(ii) Swarming motility. Strains were spot inoculated on swarm agar
(M8 minimal medium supplemented with 1 mM MgSO4, 0.2% glucose,
0.5% Bacto Casamino Acids, and 0.5% agar) plates, using 2.5-l aliquots
taken from overnight LB broth cultures (38).
(iii) Twitching motility. Isolated colonies were inoculated with a
sharp sterile toothpick inserted to the bottom of twitching medium (LB
agar) plates (37).
In all cases, 90-mm plates were filled with 30 ml of medium, briefly
dried for 2 h, and inoculated in triplicate experiments. The plates were
then wrapped with Parafilm M to prevent dehydration and incubated
at 37°C for 16 h. After incubation, the zone of motility was measured.
In the case of twitching medium, the agar-petri dish interface was
measured. If the area to be measured was irregular, two perpendicular
diameters were measured and the result was expressed as the mean of
the two values.
Biofilm formation. Biofilm assays were performed following previ-
ously described procedures (39). Briefly, 105 cells in stationary phase
were inoculated into each of four wells per strain in a microtiter plate
containing fresh LB medium, to a final volume of 100 l per well. After
incubation for 24 h at 37°C, microtiter plates were gently rinsed with
tap water. After removing all planktonic cells, plates were air dried and
stained with 125 l of a 0.1% crystal violet solution per well for 10 min.
The plates were gently rinsed with water and air dried again. The dye
was solubilized with 200 l of 30% acetic acid for 25 min at room
temperature. Once mixed by pipetting, 125 l of each well’s contents
was individually transferred to a clear flat-bottom 96-well plate. Fi-
nally, absorbance was measured at 590 nm. The final expressed values
are means for four replicates.
Determination of spontaneous mutant frequencies. The frequencies
of mutation to rifampin (300 g/ml) resistance were determined accord-
ing to previously described protocols (40). For each strain, independent
aliquots containing approximately 103 cells were inoculated into five flasks
containing 1 ml of Mueller-Hinton broth (each) and incubated at 37°C and
180 rpm for 16 to 18 h. Serial 1:10 dilutions were then plated on Mueller-
Hinton agar plates and Mueller-Hinton agar plates supplemented with 300
g/ml of rifampin. Mutant frequencies were calculated by dividing the me-
dian numbers of mutants by the median numbers of total cells in the five
independent cultures. The breakpoints used to define strong and weak mu-
tator strains were rifampin resistance mutant frequencies of 2  107 (20-
fold higher than that of wild-type PAO1) and 5  108 (5-fold higher than
that of PAO1), respectively (41). Wild-type PAO1 and its mutS-deficient mu-
tator derivative (PAOMS) were used as controls (40).
Pigment production. Production of pyocyanin and pyoverdine was
quantified as described previously (28). Briefly, bacterial strains were
grown at 37°C in Pseudomonas ACC broth for 40 h. At this time, bacteria
were pelleted by centrifugation, and the amount of the blue pigment pyo-
cyanin was evaluated by measuring the absorbance of the supernatants at
690 nm. The amount of pyoverdine was measured by fluorescence emis-
sion, by exciting the supernatants at 400 nm and measuring the emission
at 460 nm. Each experiment was performed in triplicate.
Determination of in vitro fitness through flow cytometry-coupled
competitive growth experiments. A new in vitro competition assay was
implemented from previously described protocols (27) by adding flow
cytometry as the cell-differentiating method. This novel protocol does not
require time-consuming CFU enumeration and the presence of selectable
antibiotic resistance markers to differentiate the tested strains. For this
purpose, wild-type PAO1 was fluorescently tagged at the att intergenic
neutral chromosomal locus with gfp (encoding green fluorescent protein
[GFP]), carried in mini-Tn7 constructs also containing a gentamicin
resistance gene as a resistance marker, as described previously (42).
Exponentially growing cells of the corresponding clinical strain and
GFP-tagged wild-type PAO1 (GFP-PAO1) in LB broth were then
mixed in a 1:1 ratio and diluted in 0.9% saline solution. Approximately
103 cells from each of the mixtures were inoculated into three 10-ml LB
broth flasks and grown at 37°C and 180 rpm for 16 to 18 h, correspond-
ing to approximately 20 generations. After incubation, each mixed
culture was diluted in saline solution to an optical density at 600 nm
(OD600) of 0.1. Fluorescence-assisted flow cytometry was used to dis-
tinguish between the wild-type PAO1 population producing GFP and
the clinical strain populations. The experiments were carried out using
a Beckman-Coulter Epics XL instrument. GFP-PAO1 was excited us-
ing a 488-nm blue laser and detected using a 525/40-nm filter. Data
were processed with the provided EXPO 32 software. The competition
index (CI) was defined as the final ratio between each evaluated strain
and GFP-PAO1. In the early stages, this method was validated by com-
paring results with those of CFU enumeration as the gold standard
method (27). For this purpose, competition experiments were per-
formed between 20 gentamicin-susceptible clinical strains and GFP-
PAO1 (gentamicin resistant). CIs were determined by plating strains
on LB agar and LB agar supplemented with 15 g/ml gentamicin, in
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parallel with the flow cytometry assays, validating the concordance of
both procedures. Three independent experiments were performed for
each clinical isolate, and mean CI values were recorded.
Data analysis. GraphPad Prism 5 software was used for graphical rep-
resentation and statistical analysis. Quantitative variables were compared
using the Mann-Whitney U test or the Student t test, as appropriate.
Categorical variables were compared using the 2 test. A P value of 0.05
was considered statistically significant. For hierarchical clustering of the
strains according to the 8 measured variables, the obtained values for each
isolate were divided by the median values for all isolates and then analyzed
with software available at the Eisen lab website (43; http://rana.lbl.gov
/EisenSoftware.htm [accessed 10 January 2013]).
FIG 1 (A) Minimum spanning tree of the 80 P. aeruginosa bloodstream isolates from the Spanish multicenter study. Each of the 4 resistance profiles (XDR, MDR,
ModR, and MultiS) is represented by a different color. Wide lines represent single-locus variants, and dotted lines represent multilocus variants. The sizes of the
circles represent the numbers of isolates found with the respective STs. (B) Percentages of isolates belonging to high-risk clones (ST-111, ST-175, or ST-235)
among XDR, MDR, ModR, and MultiS isolates. (C) Clonal diversity among XDR, MDR, ModR, and MultiS isolates.
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Resistance profiles and P. aeruginosa epidemic high-risk clones.
We analyzed a panel of 20 isolates from each of four established
resistance categories, i.e., XDR, MDR, ModR (resistant to 1 or 2
antimicrobial classes), and MultiS (susceptible to all antipseudo-
monal agents), recovered from a multicenter study of P. aerugi-
nosa bloodstream infections performed in 10 Spanish hospitals.
The correlations between the four resistance categories and the
epidemic high-risk clones are shown in Fig. 1. All 20 XDR isolates
belonged to high-risk clones (ST-175 or ST-111), whereas clonal
diversity was much higher for the 20 MDR isolates, which in-
cluded 8 isolates belonging to high-risk clones and 12 isolates
belonging to 11 different sporadic clones. Moreover, high-risk
clones were documented for only one of the ModR isolates and
none of the MultiS isolates, among which clonal diversity was
highest (Fig. 1). Overall, 29 of the 80 isolates studied belonged to
FIG 2 Results of swimming (A), twitching (B), and swarming (C) motility assays. (Left) Comparative analyses of the five 20-isolate groups (MultiS, ModR, MDR, XDR,
and E-XDR) studied. (Center) Comparative analyses of high-risk clones (all together) versus other clones. (Right) Comparative analyses of each of the high-risk clones
(ST-175, ST-111, and ST-235) versus other clones. *, P  0.05; **, P  0.01. The values for the reference strain PAO1 are indicated with black stars.
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high-risk clones, including 24 ST-175 and 5 ST-111 isolates, and
these were detected in 8 of the 10 hospitals, with a wide geograph-
ical distribution covering all 4 regions participating in the study.
Isolates belonging to the third international high-risk clone, ST-
235, were not detected in our multicenter study of bloodstream
infections, but other recent studies also detected this clone in
Spain, linked either to a large outbreak of GES-5 class A carbap-
enemase-producing P. aeruginosa in a hospital in Madrid (17) or
to the class B carbapenemase VIM-13, which is autochthonous to
the Balearic Islands (33). To widen the diversity and spectrum of
high-risk clone isolates included in the subsequent analysis of
biological markers, we added another, fifth panel (designated E-
XDR), composed of 20 previously characterized XDR isolates be-
longing to the three major epidemic high-risk clones (ST-175 [n 
6], ST-111 [n  7], and ST-235 [n  7]), producing outbreaks in
several different hospitals, and presenting multiple different com-
binations of chromosomal resistance mechanisms and/or hori-
zontally acquired -lactamases.
Defective motility in widespread epidemic high-risk clones.
It is widely accepted that the diverse repertoire of bacterial motil-
ity systems, including swimming (flagellum-mediated motility in
liquid media), twitching (type IV fimbria-mediated motility with
surface adherence), and swarming (flagellum-mediated, coordi-
nated movement across surfaces) motility, plays a pivotal role in
the colonization of fluids and surfaces, including those found in
the nosocomial environment or the patient’s epithelial tissues
(44). Motility systems are also well-established virulence determi-
nants, playing a major role in tissue invasion during infections
(45). Therefore, differentially expressed motility systems were
strong candidates to be involved in the clonal success of P. aerugi-
nosa high-risk clones. Figure 2 shows the results for swimming,
twitching, and swarming motility assays. As shown, no statistically
significant differences were observed for any of the three motility
systems between clonally diverse MultiS and ModR isolates, indi-
cating that single resistance mechanisms of P. aeruginosa clinical
strains do not have a uniform impact on swimming, twitching, or
swarming motility. On the other hand, in contrast to our initial
expectations, MDR/XDR high-risk clones were found to be asso-
ciated significantly with defective swimming, twitching, and
swarming motility. Moreover, this association was significant for
all three high-risk clones and all three motility systems individu-
ally, except for the case of ST-235 and swimming motility (Fig. 2).
FIG 3 Results of pyoverdine (A) and pyocyanin (B) production assays. (Left) Comparative analyses of the five 20-isolate groups (MultiS, ModR, MDR, XDR, and
E-XDR) studied. (Center) Comparative analyses of high-risk clones (all together) versus other clones. (Right) Comparative analyses of each of the high-risk
clones (ST-175, ST-111, and ST-235) versus other clones. *, P  0.05; **, P  0.01. The values for the reference strain PAO1 are indicated with black stars.
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Whether this strong association of high-risk clones with defective
motility is driven by the activation of specific regulatory pathways
in these lineages, negative selection of metabolically costly motil-
ity systems, or positive selection of mechanisms to evade the host
immune system (i.e., fimbriae and flagella are key targets for the
recognition of pathogens by the immune system) still needs to be
explored. In any case, the presented results clearly indicate that
none of the motility systems are required for the successful spread
of these global clones.
Defective pigment production in widespread epidemic high-
risk clones. One of the most characteristic features of P. aerugi-
nosa is the production of pigments. Indeed, in addition to confer-
ring a distinctive blue-green color to P. aeruginosa colonies,
pyocyanin (a redox-active phenazine toxin) and pyoverdine (a
siderophore) are well known to play a major role in bacterial phys-
iology and pathogenesis (46, 47). Therefore, differential produc-
tion of pigments was also a strong candidate to be involved in the
clonal success of P. aeruginosa high-risk clones. Figure 3 shows the
FIG 4 Results of biofilm formation (A) and in vitro fitness (B) assays and rifampin resistance (Rifr) mutant frequencies (C). (Left) Comparative analyses of the
five 20-isolate groups (MultiS, ModR, MDR, XDR, and E-XDR) studied. (Center) Comparative analyses of high-risk clones (all together) versus other clones.
(Right) Comparative analyses of each of the high-risk clones (ST-175, ST-111, and ST-235) versus other clones. *, P  0.05; **, P  0.01. The values for the
reference strain PAO1 are indicated with black stars.
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results of pyocyanin and pyoverdine production assays. Once
more, significant differences were not observed for either pyo-
cyanin or pyoverdine between MultiS and ModR isolates. On the
other hand, again in contrast to our initial expectations, MDR/
XDR high-risk clones were found to be associated significantly
with defective pigment production (Fig. 3). Moreover, this asso-
ciation was significant for both pigments in all three high-risk
clones individually, indicating that defective pyocyanin and
pyoverdine production is a common signature of these globally
spread strains.
Increased biofilm formation in widespread epidemic high-
risk clones. One of the major bacterial strategies for colonizing
nearly all types of environments, from natural ecosystems to nos-
ocomial settings and human hosts, is the development of struc-
tured multicellular communities embedded in a polymeric ma-
trix, known as biofilms (48). Bacterial biofilms are highly resistant
to antibiotics and effectors of the immune system (such as anti-
bodies and phagocytes) and represent a major source of persistent
infections (49). Therefore, an enhanced capacity to form biofilms
was also a strong candidate to be involved in the clonal success of
P. aeruginosa high-risk clones. Figure 4A shows the results of bio-
film production assays. Once again, biofilm formation was not
significantly different in MultiS and ModR isolates. However, in
contrast to motility and pigment production, biofilm formation
was significantly enhanced globally in high-risk clones, and indi-
vidually for ST-175 and ST-111 isolates (Fig. 4A). Therefore, the
results so far indicate that MDR/XDR epidemic high-risk clones
are associated with defective motility and pigment production but
increased biofilm formation, which, interestingly, are attributes
that resemble the phenotypic signature observed during P. aerugi-
nosa adaptation in chronic infections (49, 50). Thus, the adaptive
processes for long-term persistence in chronic infection and
global clonal success in the nosocomial environment appear to
have common elements, perhaps through one of the several po-
tential regulatory networks connecting all these elements, includ-
ing antibiotic resistance, motility, pigment production, and bio-
film formation (23).
In vitro fitness is not higher in widespread epidemic high-
risk clones. Certainly, a major issue to consider in analyzing
clonal success is bacterial fitness. It is well known that antibiotic
resistance mechanisms may impose a fitness cost but also that this
cost may be minimized through compensatory mutations (21,
26). Although fitness is a relative parameter that obviously will be
highly dependent on the specific environmental conditions faced
by microorganisms, standardized in vitro competitive growth as-
says are useful for estimating the metabolic cost of antibiotic re-
sistance mechanisms (21). Figure 4B shows the results for compe-
tition assays. Once again, significant differences were not observed
between clonally diverse MultiS and ModR isolates, indicating
that single resistance mechanisms of P. aeruginosa clinical strains
do not have a uniform impact on fitness. However, competition
indexes were significantly lower for high-risk clones, showing that
FIG 5 Hierarchical clustering of the strains according to the 8 measured vari-
ables (swimming, twitching, and swarming motility, biofilm formation, pro-
duction of pyoverdine and pyocyanin, spontaneous [rifampin resistance] mu-
tant frequencies, and in vitro CI), using the software available at the Eisen lab
website (http://rana.lbl.gov/EisenSoftware.htm). Green and red indicate that
the values are lower and higher than the median, respectively. The acquired
-lactamases produced are also indicated.
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enhanced in vitro fitness does not explain the clonal success of
these widely spread clones.
Increased spontaneous mutation rates in some widespread
epidemic high-risk clones. A major adaptive strategy of bacterial
pathogens facing new environments or adverse conditions is the
selection of variants with increased mutation rates, known as mu-
tators. Indeed, variants with highly increased mutation rates
(strong mutators), due to a defective DNA mismatch repair sys-
tem, are found to be very frequent in P. aeruginosa chronic infec-
tions linked to antibiotic resistance, although their prevalence in
acute nosocomial infections is very low (40, 41, 48). Moderately
increased mutation rates (weak mutator phenotypes) were also
shown to be selected positively in chronic infections linked to
antibiotic resistance (51). However, so far, there was no available
information on the mutation rates of P. aeruginosa high-risk
clones. Interestingly, as shown in Fig. 4C, spontaneous mutant
frequencies were found to be significantly higher for high-risk
clones, although individually, differences were significant only for
ST-111 isolates. Moreover, while none of the 100 isolates were
classified as strong mutators, a significantly larger proportion of
weak mutators was detected among high-risk clones than among
the other clones (20.4% versus 3.9%; P  0.01). Therefore, weak
mutator phenotypes could play a role in the high adaptability
required for global dissemination of high-risk clones.
Concluding remarks. In summary, our results indicate that P.
aeruginosa high-risk clones are significantly associated with a de-
fined set of biological parameters which include increased biofilm
formation and mutant frequencies but reduced motility (twitch-
ing, swimming, and swarming), pigment (pyoverdine and pyo-
cyanin) production, and in vitro fitness (Fig. 5). The defined bio-
logical markers of P. aeruginosa high-risk clones, which present
certain similarities with those resulting from adaptation to
chronic infections, could be useful for the future design of specific
treatment and infection control strategies. Moreover, while the
investigated biological parameters were chosen for their potential
relevance to clonal success, the presence of specific virulence traits
in high-risk clones that determine a higher or lower disease sever-
ity still needs to be explored in further studies.
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